6331 - 6340 of 9118 Results
Title
Year
-
OPENTitle: Putting participants and study partners FIRST when clinical trials end earlyJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 18Issue #: 12Start Page: 2736End Page: 2746Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1002/alz.12732Best OA location URL: https://doi.org/10.1002/alz.12732Citation Count: 12
- Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to Action2022OPENTitle: Including People with Parkinson’s Disease in Clinical Study Design and Execution: A Call to ActionJournal Name: Journal of Parkinson's DiseasePublisher: SAGE PublicationsVol: 12Issue #: 4Start Page: 1359End Page: 1363Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.3233/jpd-223190Best OA location URL: https://content.iospress.com:443/download/journal-of-parkinsons-disease/jpd223190?id=journal-of-parkinsons-disease%2Fjpd223190Citation Count: 15
-
OPENTitle: Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s diseaseJournal Name: Journal of Biopharmaceutical StatisticsPublisher: Informa UK LimitedVol: 35Issue #: 5Start Page: 981End Page: 1000Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/10543406.2023.2170400Best OA location URL: https://doi.org/10.1080/10543406.2023.2170400Citation Count: 8
- Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discounting2020RESTRICTEDTitle: Baseline-dependency: How genotype and signaled delays influence amphetamine's effects on delay discountingJournal Name: Pharmacology Biochemistry and BehaviorPublisher: Elsevier BVVol: 199Issue #:Start Page: 173070End Page: 173070Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.pbb.2020.173070Citation Count: 10
- Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease Patient2017RESTRICTEDTitle: Addition of Filgrastim (Neupogen) for Clozapine Rechallenge in the Case of Parkinson Disease PatientJournal Name: Clinical NeuropharmacologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 40Issue #: 5Start Page: 233End Page: 234Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/wnf.0000000000000230Citation Count: 7
-
OPENTitle: Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's diseaseJournal Name: Neuroscience LettersPublisher: Elsevier BVVol: 480Issue #: 1Start Page: 78End Page: 82Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neulet.2010.06.009Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/2943649Citation Count: 219
-
OPENTitle: Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trialJournal Name: Stem Cell Research & TherapyPublisher: Springer Science and Business Media LLCVol: 16Issue #: 1Start Page: 493End Page: 493Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1186/s13287-025-04577-yBest OA location URL: https://stemcellres.biomedcentral.com/counter/pdf/10.1186/s13287-025-04577-yCitation Count: 4
-
OPENTitle: Mechanisms of Alpha-Synuclein-Seeded Aggregation in Neurons Revealed by Fluorescence Lifetime ImagingJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 16Issue #: 11Start Page: 2128End Page: 2140Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1021/acschemneuro.5c00236Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.5c00236?ref=article_openPDFCitation Count: 2
-
OPENTitle: Benchmarking privacy and utility in synthetic tabular cohorts for Alzheimer's disease researchJournal Name: Alzheimer's & Dementia: Diagnosis, Assessment & Disease MonitoringPublisher: WileyVol: 18Issue #: 3Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/dad2.70430Best OA location URL: https://doi.org/10.1002/dad2.70430Citation Count: 0
-
OPENTitle: Olfactory impairment predicts cognitive decline in early Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 25Issue #:Start Page: 45End Page: 51Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2016.02.013Best OA location URL: http://doi.org/10.1016/j.parkreldis.2016.02.013Citation Count: 124